Integris Medtech has received SEBI approval for its ₹925 crore IPO, paving the way for a major public listing. The fresh issue and offer for sale will fund manufacturing scale-up, R&D in advanced medical devices, international market entry, and debt reduction accelerating the company’s ambition to become a global player in high-value medtech segments.
Glimpse:
The ₹925 crore IPO comprises a fresh issue of ₹700 crore and an offer for sale of ₹225 crore. Proceeds will support capacity expansion for surgical robotics, interventional cardiology devices, orthopaedics, and diagnostics; global regulatory clearances; and strategic acquisitions. With SEBI clearance secured, Integris is set to tap public markets to capitalize on India’s growing medtech export potential and domestic demand.
Integris Medtech, a rising Indian manufacturer of high-end medical devices, has obtained approval from the Securities and Exchange Board of India (SEBI) to proceed with its ₹925 crore initial public offering. The IPO comprising a fresh issue of ₹700 crore and an offer for sale of ₹225 crore marks one of the largest medtech listings in recent years and reflects strong investor confidence in India’s fast-growing medical devices sector.
The company specializes in complex, high-margin products including structural heart devices, neurovascular interventions, orthopaedic implants, minimally invasive surgical tools, and advanced diagnostics. Integris has built a robust export presence in over 40 countries and supplies to leading global OEMs while maintaining strong domestic growth through government tenders and private hospital chains.
Key uses of IPO proceeds include:
Capacity expansion new greenfield facilities and upgrades to existing plants for higher output of Class III devices R&D and innovation accelerating development of next-gen robotics, bioresorbable stents, and AI-integrated diagnostics Global market penetration funding US FDA, CE Mark, and other regulatory clearances; establishing overseas sales offices Debt reduction & general corporate purposes strengthening balance sheet for acquisitions and working capital
The IPO comes at a pivotal time for India’s medtech industry, which is benefiting from PLI schemes, National Medical Devices Policy 2023, and rising global demand for cost-effective, high-quality devices. Integris aims to use public capital to reduce import dependence, capture more export share, and compete with global leaders in high-growth segments like structural heart and neurointervention.
Anchor and pre-IPO investor interest has reportedly been strong, with the issue expected to open for subscription in the coming weeks.
“This IPO is a milestone in our journey to become a global medtech leader from India bringing world-class innovation and manufacturing to patients everywhere.”
By
HB Team
Related News
